OpportunityAnalyzer: Acute Myeloid Leukemia – Opportunity Analysis and Forecasts to 2026

Invite Credit Card Holder to pay

Requester Details

Credit Card Holder Details

Company Details

Message to be included

Acute myeloid leukemia (AML) is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. Although a number of acquired genetic and molecular abnormalities have been implicated in the manifestation of AML and disease progression, in most cases the stimuli causing these abnormalities to occur have not been identified.

Major drivers of the AML market in the 7MM will include an increasing number of elderly incident cases of AML, particularly in the US, the launch of premium-priced therapies, including AbbVie/Roche’s Venclexta, Celgene’s enasidenib and CC-486, and Actinium’s Iomab-B for elderly AML patients; Daiichi Sankyo’s quizartinib and Astellas’ gilteritinib for FLT3–mutated AML; and Jazz’s Vyxeos for newly diagnosed elderly secondary AML patients, and an increasing branded drug treatment rate, particularly among elderly patients.

Barriers to the growth of the AML market in the 7MM will include a high enrollment rate of AML patients in clinical trials in the 5EU, the US, and Japan, pressure for cost-consciousness, particularly in the EU, limited adoption of the branded therapies due to positioning of most of them in combination with the relatively toxic current standard-of-care (SOC) regimens, loss of patent protection of Vidaza,

Dacogen, Rydapt, and the prospective branded therapies Vyxeos and guadecitabine.

Key Questions Answered

The AML market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the AML market?

How will new pipeline agents such as Rydapt, enasidenib, Mylotarg, Vyxeos, and Venclexta impact the AML market?

The current AML market is dominated by generic chemotherapies. How will the advent of targeted prescription drugs change the drug treatment landscape in AML? How will the drug treatment rate change over the next five years? What are the key drivers and barriers to this change?

Scope

Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized AML therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in nine patient segments , forecast from 2016 to 2026.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AML therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AML. The most promising candidate in Phase III development are profiled.

Analysis of the current and future market competition in the global AML market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global AML market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AML market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

AbbVie

Actinium Pharmaceuticals

Agios Pharmaceuticals

Ambit Biosciences

Arog Pharmaceuticals

Astellas Pharma

Astex Pharmaceuticals

Athenex

BioLineRx

Boehringer Ingelheim

Boston Biomedical

Bristol-Myers Squibb

Celator

Celgene

CTI BioPharma ...

AbbVie

Actinium Pharmaceuticals

Agios Pharmaceuticals

Ambit Biosciences

Arog Pharmaceuticals

Astellas Pharma

Astex Pharmaceuticals

Athenex

BioLineRx

Boehringer Ingelheim

Boston Biomedical

Bristol-Myers Squibb

Celator

Celgene

CTI BioPharma

Cyclacel

Daiichi Sankyo

Delta-Fly

Eisai

EpiZyme

Erytech Pharma

Fujifilm

Gamida Cell

Genentech

Gilead Sciences

Helsinn

H3 Biomedicine

Incyte

Jazz

Johnson & Johnson

Kyowa Hakko Kirin

MEI Pharma

Merck & Co

Merus

Novartis

OncoTherapy Science

Otsuka

Pfizer

Roche

Seattle Genetics

Stemline

Sumitomo Dainippon

Sunesis

Synta

Syros

Takara Bio

Takeda

Teva

Tolero

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Acute Myeloid Leukemia: Executive Summary

2.1 ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Acute Myeloid Leukemia: Executive Summary

2.1 New Entrants Will Drive Strong Growth in the US and EU AML Market from 2016 to 2026

2.2 R&D Strategies Target Underserved Patients and Aim to Circumvent Historical Difficulties

2.3 High Unmet Needs Exist in the AML Market, Especially for Elderly and Relapsed/Refractory Patients

2.4 Pipeline Agents Will Offer Incremental Improvements Over Current Therapies

2.5 Significant Opportunity Remains For Effective Therapies in AML

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Pathophysiology

4.1.2 Classification

4.1.3 Cytogenetic and Molecular Abnormalities

4.2 Prognosis

4.3 Quality of Life

4.4 Symptoms

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 Incidence

5.3.2 Relative Survival

5.3.3 Subtypes

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods - Population

5.4.3 Forecast Assumptions and Methods - Incidence

5.4.4 Forecast Assumptions and Methods - Relative Survival

5.4.5 Forecast Assumptions and Methods – Subtypes of AML

5.4.6 Forecast Assumptions and Methods – Mutations and Biomarkers

5.4.7 Forecast Assumptions and Methods – Risk Groups

5.5 Epidemiological Forecast for Acute Myeloid Leukemia (2016–2026)

5.5.1 Adjusted Diagnosed Incident Cases of AML

5.5.2 Age-Specific Diagnosed Incident Cases of AML

5.5.3 Diagnosed Incident Cases of APL

5.5.4 Diagnosed Incident Cases of Secondary AML

5.5.5 Diagnosed Incident Cases of AML by Mutations and Biomarkers

5.5.6 Diagnosed Incident Cases of AML by Risk Groups

5.5.7 Five-Year Diagnosed Prevalent Cases of AML

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Current Treatment Options

6.1 Overview

6.2 Diagnosis and Treatment

6.2.1 Diagnosis

6.2.2 Treatment Guidelines and Leading Prescribed Drugs

6.3 Response Criteria and Outcome Measures

6.4 Clinical Practice

6.4.1 Younger AML Patients

6.4.2 Older AML Patients

6.5 Hematopoietic Stem Cell Transplant (HSCT)

6.6 Monitoring for Minimal Residual Disease

6.7 Acute Promyelocytic Leukemia

6.8 Product Profiles – Major Brands

6.8.1 Cytarabine

6.8.2 Dacogen (decitabine)

6.8.3 Vidaza (azacitidine)

6.8.4 Mylotarg (gemtuzumab ozogamicin)

6.8.5 Rydapt (midostaurin)

6.8.6 Other Therapeutic Classes for AML

7 Unmet Needs Assessment and Opportunity Analysis

7.1 Overview

7.2 Therapies That Prolong the Overall Survival of AML Patients

7.2.1 Unmet Need

7.2.2 Gap Analysis

7.2.3 Opportunity

7.3 Elimination of Minimal Residual Disease

7.3.1 Unmet Need

7.3.2 Gap Analysis

7.3.3 Opportunity

7.4 Therapies That Achieve Durable Complete Remission in AML Patients

7.4.1 Unmet Need

7.4.2 Gap Analysis

7.4.3 Opportunity

7.5 Safer Treatment Options

7.5.1 Unmet Need

7.5.2 Gap Analysis

7.5.3 Opportunity

7.6 Maintenance Therapies

7.6.1 Unmet Need

7.6.2 Gap Analysis

7.6.3 Opportunity

7.7 Improvement in Guidelines Directing the Optimum Course of Therapy

7.7.1 Unmet Need

7.7.2 Gap Analysis

7.7.3 Opportunity

7.8 Therapies with More Convenient Administration and Dosing Regimens

7.8.1 Unmet Need

7.8.2 Gap Analysis

7.8.3 Opportunity

8 Research and Development Strategies

8.1 Overview

8.1.1 Targeting Multiple Patient Segments

8.1.2 Developing Novel Drugs in Combination with Established Therapies

8.1.3 Targeting Elderly AML Patients

8.1.4 Investigating New Targets Involved in the Pathogenesis of AML

8.1.5 Alliances Between Academic Groups and Pharmaceutical Companies

8.2 Clinical Trial Design

8.2.1 Current Clinical Trial Design

8.2.2 Selection of the Appropriate Efficacy Endpoints to Support Regulatory Approval

8.2.3 Selection of Active Comparator

8.2.4 Randomization of Stratification of Patients

8.2.5 Future Trends in Clinical Trial Design

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.3 Hypomethylating Agents (HMAs)

9.3.1 CC-486 (oral azacitidine)

9.3.2 Guadecitabine (SGI-110)

9.4 FLT3 Tyrosine Kinase Inhibitors

9.4.1 Gilteritinib (ASP2215)

9.4.2 Quizartinib (AC220)

9.4.3 Crenolanib Besylate

9.5 Anti-CD33 Antibody Drug Conjugates (ADCs)

9.5.1 Vadastuximab Talirine (SGN-CD33A)

9.6 IDH2 Inhibitors

9.6.1 Enasidenib (AG-221)

9.7 Other Targeted Therapies

9.7.1 Venclexta/Venclyxto (venetoclax)

9.7.2 Idasanutlin

9.7.3 Pracinostat

9.7.4 Iomab-B

9.7.5 Volasertib (BI 6727)

9.7.6 Ganetespib (STA-9090)

9.8 Chemotherapy

9.8.1 Vyxeos (CPX-351)

9.8.2 Qinprezo (vosaroxin)

9.8.3 Sapacitabine (CYC682)

9.9 HSCT Alternatives

9.9.1 NiCord

9.10 Innovative Early-Stage Approaches

9.10.1 Epigenetic Modulators

9.10.2 Targeted Therapies

9.10.3 Immunotherapies

9.11 Other Drugs in Development

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.4 Forecasting Methodology

11.4.1 Diagnosed Patients

11.4.2 Percent Drug-Treated Patients

11.4.3 Drugs Included in Each Therapeutic Class

11.4.4 Launch and Patent Expiry Dates

11.4.5 General Pricing Assumptions

11.4.6 Individual Drug Assumptions

11.4.7 Generic Erosion

11.4.8 Pricing of Pipeline Agents

11.5 Primary Research – KOLs Interviewed for this Report

11.5.1 KOLs

11.6 Primary Research – Prescriber Survey

11.7 About the Authors

11.7.1 Analyst

11.7.2 Therapy Area Director

11.7.3 Managing Epidemiologist

11.7.4 Global Director of Therapy Analysis and Epidemiology

11.7.5 Global Head and EVP of Healthcare Operations Strategy

11.8 About GlobalData

11.9 Contact Us

11.10 Disclaimer

List of tables

Table 1: Acute Myeloid Leukemia: Key Metrics in the Seven Major Pharmaceutical Markets, 2016–2026

Table 2: Classification of AML Subtypes – WHO System

Table 3 ...

Table 1: Acute Myeloid Leukemia: Key Metrics in the Seven Major Pharmaceutical Markets, 2016–2026

Table 2: Classification of AML Subtypes – WHO System

Table 3: Classification of AML Subtypes – FAB System

Table 4: Common Cytogenetic Abnormalities in AML

Table 5: Symptoms of AML

Table 6: Risk Factors for AML in Adults

Table 7: AML Coding System by Country

Table 8: Five-Year Relative Survival of AML by Age, 2016

Table 9: Risk Group Classification Guidelines

Table 10: 7MM, Adjusted Diagnosed Incident Cases of AML, Ages ≥18 Years, Both Sexes, Select Years 2016–2026

Table 11: 7MM, Age-Specific Adjusted Diagnosed Incident Cases of AML, Both Sexes, 2016

Table 12: 7MM, Mutations and Biomarkers in Diagnosed Incident Cases of AML, Ages ≥18 Years, Both Sexes, 2016

Table 13: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Ages ≥18 Years, Both Sexes, Select Years 2016–2026

Table 14: Leading Treatments for AML

Table 15: Treatment Guidelines for Acute Myeloid Leukemia

Table 16: Most Commonly Used Regimens in Acute Myeloid Leukemia

Table 17: Types of Responses – AML

Table 18: Outcome Measures in AML

Table 19: Induction and Consolidation Regimens for APL by Patient Risk Group

Table 20: Product Profile – Cytarabine (generic)

Table 21: Cytarabine SWOT Analysis

Table 22: Product Profile – Dacogen

Table 23: Efficacy of Dacogen versus Physicians’ Choice of Treatment (DACO-016 Trial; NCT00260832)

Table 24: Safety of Dacogen (decitabine) in AML Patients (DACO-016 Trial; NCT00260832)

Table 25: Dacogen SWOT Analysis

Table 26: Product Profile – Vidaza

Table 27: Efficacy of Vidaza versus Conventional Care Regimens in Newly Diagnosed or Secondary Elderly AML Patients with >30% Blasts (NCT01074047; AML-001)

Table 28: Efficacy of Vidaza plus Revlimid (lenalidomide) in Newly Diagnosed Elderly AML Patients (NCT00890929)

Table 29: Safety of Vidaza (azacitidine) in Newly Diagnosed or Secondary Elderly AML Patients with >30% Blasts (NCT01074047; AML-001)

Table 30: Safety of Vidaza + Revlimid in Newly Diagnosed Elderly AML Patients (NCT00890929)

Table 31: Vidaza SWOT Analysis

Table 32: Product Profile – Mylotarg (Gemtuzumab Ozogamicin [GO])

Table 33: Efficacy of Mylotarg versus Best Supportive Care in Previously Untreated Elderly AML Patients (NCT00091234; AML-19)

Table 34: Efficacy Analysis of Mylotarg in the ALFA 0701 Phase III Trial (EudraCT 2007-002933-36)

Table 35: Safety of Mylotarg in Previously Untreated Elderly AML Patients (NCT00091234; AML-19)

Table 36: Safety of Mylotarg in Previously Untreated Elderly AML Patients (EudraCT 2007-002933-36; ALFA-001)

Table 37: Mylotarg SWOT Analysis

Table 38: Product Profile – Midostaurin

Table 39: Efficacy of Rydapt in Combination with Azacitidine in Patients with AML/MDS (Trial NCT01202877)

Table 40: Safety of Rydapt in Combination with Vidaza in Patients with AML/MDS (>65 years of age) (NCT01202877)

Table 41: Rydapt SWOT Analysis

Table 42: Other Therapeutic Agents Prescribed for AML

Table 43: Overall Unmet Needs in AML – Current Level of Attainment

Table 44: Clinical Trial Design of Key Registrational Trials in AML Patients Who Are Eligible for Intensive Chemotherapy

Table 45: Clinical Trial Design of Key Registrational Trials in AML Patients Who Are Not Eligible for Intensive Chemotherapy

Table 46: Clinical Trial Design of Key Registrational Trials of Late Stage Pipeline Products Evaluated in the Maintenance Setting Following First-Line Consolidation Treatment

Table 47: Clinical Trial Design of Key Registrational Trials of Late Stage Pipeline Products Evaluated in Patients with Relapsed/Refractory AML

Table 48: AML – Late-Stage Pipeline, 2017

Table 49: Product Profile – CC-486

Table 50: Efficacy of CC-486 in AML Patients

Table 51: Efficacy of CC-486 Extended Dosing Schedules in WHO-Defined RAEB-1 or RAEB-2 MDS (Ad hoc Analysis of Two Ongoing Phase I/II Studies)

Table 52: Safety of CC-486 in AML Patients

Table 53: CC-486 SWOT Analysis

Table 54: Product Profile – Guadecitabine

Table 55: Efficacy of Five- and 10-day Regimens of Guadecitabine in Previously Untreated Elderly AML Patients

Table 56: Efficacy of Guadecitabine in Elderly Patients Ineligible for Intensive Chemotherapy (Trial NCT01261312)

Table 57: Efficacy of Guadecitabine + Chemotherapy in Elderly Newly Diagnosed AML

Table 58: Efficacy of Guadecitabine in Relapsed/Refractory AML

Table 59: Safety of Guadecitabine in Elderly Patients Ineligible for Intensive Chemotherapy

Table 60: Safety of Guadecitabine in Previously Untreated Elderly AML Patients

Table 61: Guadecitabine SWOT Analysis

Table 62: Product Profile – Gilteritinib

Table 63: Efficacy of Gilteritinib in Refractory/Relapsed AML Patients (Trial NCT02014558)

Table 64: Gilteritinib SWOT Analysis

Table 65: Product Profile – Quizartinib

Table 66: Efficacy of Quizartinib in FLT3-ITD(+) Refractory/Relapsed AML Patients (Trial NCT01565668)

Table 67: Efficacy of Quizartinib in FLT3-ITD(+) Refractory/Relapsed AML Patients as a Bridge to HSCT

Table 68: Safety of Quizartinib in FLT3-ITD(+) Refractory/Relapsed AML Patients (Trial NCT01565668)

Table 69: Quizartinib SWOT Analysis

Table 70: Product Profile – Crenolanib Besylate

Table 71: Patient Characteristics in the Two Phase II Trials of Crenolanib

Table 72: Efficacy of Crenolanib in Relapsed/Refractory FLT3-ITD and/or TKD AML

Table 73: Efficacy of Crenolanib + Standard Induction Chemotherapy in Newly Diagnosed FLT3-Mutated AML

Table 74: Safety of Crenolanib in Relapsed/Refractory FLT3-Mutated AML

Table 75: Crenolanib SWOT Analysis

Table 76: Product Profile – Vadastuximab Talirine

Table 77: Patient Characteristics in the Phase I Trial of Vadastuximab Talirine (NCT01902329)

Table 78: Efficacy Analysis of Vadastuximab Talirine Monotherapy or in Combination with an HMA

Table 79: Efficacy Analysis of Vadastuximab Talirine in Combination with 7+3

Table 80: Efficacy Analysis of Vadastuximab Talirine Consolidation and Maintenance Setting

Table 81: Vadastuximab Talirine SWOT Analysis

Table 82: Product Profile – Enasidenib (AG-221)

Table 83: Efficacy Analysis of Enasidenib in Relapsed/Refractory AML (NCT01915498)

Table 84: Enasidenib SWOT Analysis

Table 85: Product Profile – Venclexta (Venetoclax)

Table 86: Efficacy Analysis of Venclexta in Elderly Patients with Newly Diagnosed AML (NCT02203773)

Table 87: Efficacy of Venclexta + LDAC Regimen in Elderly Patients (NCT02287233)

Table 88: Safety Profile of Venclexta in Combination with Azacitidine or Decitabine (NCT02203773)

Table 89: Venclexta SWOT Analysis

Table 90: Product Profile – Idasanutlin

Table 91: Efficacy Analysis of Idasanutlin + Cytarabine in Relapsed/Refractory AML

Table 92: Idasanutlin SWOT Analysis

Table 93: Product Profile – Pracinostat

Table 94: Efficacy Analysis of Pracinostat + Azacitidine in Elderly Patients with Newly Diagnosed AML

Table 95: Safety Profile of Pracinostat + Azacitidine in Newly Diagnosed Elderly AML Patients

Table 96: Pracinostat SWOT Analysis

Table 97: Product Profile – Iomab-B

Table 98: Safety Profile of Iomab-B

Table 99: Iomab-B SWOT Analysis

Table 100: Product Profile – Volasertib

Table 101: Initial Efficacy Analysis of Volasertib + LDAC in the Phase III POLO-AML-2 Trial

Table 102: Efficacy of Volasertib with LDAC in Elderly AML Patients Ineligible for Intensive Therapy (Trial NCT00804856)

Table 103: Safety of Volasertib with LDAC in Elderly AML Patients Ineligible for Intensive Therapy (Trial NCT00804856)

Table 104: Volasertib SWOT Analysis

Table 105: Product Profile – Ganetespib

Table 106: Efficacy Analysis of Ganetespib + LDAC in the Phase III AML-LI-1 Trial

Table 107: Safety Analysis of Ganetespib + LDAC in the Phase III AML-LI-1 Trial

Table 108: Ganetespib SWOT Analysis

Table 109: Product Profile – Vyxeos

Table 110: Patients Characteristics in the Phase III Trial (Celator, NCT01696084) of Vyxeos

Table 111: Efficacy of Vyxeos versus 7+3 in the Phase III Trial (Celator, NCT01696084)

Table 112: Subgroup Efficacy Analysis of the Phase III Trial (Celator, NCT01696084) of Vyxeos in sAML

Table 113: Post-HSCT Efficacy Analysis of the Phase III Trial (Celator, NCT01696084) of Vyxeos in sAML

Table 114: Efficacy of Vyxeos versus 7+3 Regimen in Patients Between 60 and 75 Years of Age with Newly Diagnosed AML (Trial NCT00788892)

Table 115: Efficacy of Vyxeos in AML Patients (18–65 years of age) in First Relapse (Trial NCT00822094)

Table 116: Safety Profile of Vyxeos in Elderly sAML

Table 117: Safety of Vyxeos in AML Patients (18–65 years of age) in First Relapse (Trial NCT00822094)

Table 118: Vyxeos SWOT Analysis

Table 119: Product Profile – Qinprezo

Table 120: Efficacy of Qinprezo in Refractory/Relapsed AML Patients of All Ages (Trial NCT01191801; VALOR)

Table 121: Efficacy of Qinprezo in Elderly (60 years and older) Refractory/Relapsed AML Patients After a Longer Follow-up Time(Trial NCT01191801; VALOR)

Table 122: Safety of Qinprezo in Refractory/Relapsed AML Patients of All Ages (Trial NCT01191801; VALOR)

Table 123: Qinprezo SWOT Analysis

Table 124: Product Profile – Sapacitabine

Table 125: Efficacy of Sapacitabine in Elderly Patients with Newly Diagnosed AML (>70 years) (Trial NCT01303796; SEAMLESS)

Table 126: Safety of Sapacitabine in Elderly Patients with Newly Diagnosed AML (Trial NCT01303796)

Table 127: Sapacitabine SWOT Analysis

Table 128: Product Profile – NiCord

Table 129: NiCord SWOT Analysis

Table 130: Early-Stage Pipeline Products in AML

Table 131: Drugs in Development for AML, 2017

Table 132: Clinical Benchmark of Key Pipeline Drugs – Therapies For Elderly AML Patients Who Are Not Eligible For Intensive Therapy ( 60 Years and Older)

Table 133: Clinical Benchmark of Key Pipeline Drugs – Therapies for Young and Elderly AML Patients Who Are Eligible For Intensive Therapy (Ages 18 and Older)

Table 134: Clinical Benchmark of Key Pipeline Drugs – Therapies for Young and Elderly AML Patients Who Are Eligible For Intensive Therapy (Ages 18 and Older)—continued from Table 124

Table 135: Clinical Benchmark of Key Pipeline Drugs – FLT3 TKIs (Ages 18 and Older)

Table 136: Commercial Benchmark of Key Pipeline Drugs – Therapies for Elderly AML Patients Who Are Not Eligible For Intensive Therapy (60 Years and Older)

Table 137: Commercial Benchmark of Key Pipeline Drugs – Therapies for Young and Elderly AML Patients Who Are Eligible For Intensive Therapy (Ages 18 and Older )

Table 138: Commercial Benchmark of Key Pipeline Drugs – Therapies for Young and Elderly AML Patients Who Are Eligible For Intensive Therapy (Ages 18 and Older )—continued from Table 128

Table 139: Commercial Benchmark of Key Pipeline Drugs – FLT3 TKIs

Table 140: Top-Line Sales Forecasts ($m) for AML, 2016–2026

Table 141: Key Events Impacting Sales of AML Products, 2016–2026

Table 142: AML Market – Global Drivers and Barriers, 2016‒2026

Table 143: Sales Forecast ($M) for AML in the US, 2016–2026

Table 144: Sales Forecast ($M) for AML in the 5EU, 2016–2026

Table 145: Sales Forecast ($M) for AML in Japan, 2016–2026

Table 146: Key Historical and Projected Launch Dates for AML

Table 147: Key Historical and Projected Patent Expiry Dates for AML

Table 148: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of figures

Figure 1: Global Sales for AML by Country/Region, 2016 and 2026

Figure 2: Competitive Assessment of Marketed And Pipeline Agents in Elderly AML Patients ...

Figure 1: Global Sales for AML by Country/Region, 2016 and 2026

Figure 2: Competitive Assessment of Marketed And Pipeline Agents in Elderly AML Patients Who Are Not Eligible For Intensive Therapy (60 Years And Older), 2016–2026

Figure 3: Competitive Assessment of Marketed And Pipeline Agents in Young and Elderly AML Patients Who Are Eligible For Intensive Therapy (18 Years And Older), 2016–2026

Figure 4: Competitive Assessment of Marketed And Pipeline Agents in Patients With FLT3+ AML (18 Years And Older), 2016–2026

Figure 5: Comparison of Normal and Leukemia Blood Cell Differentiation

Figure 6: 7MM, Age-Standardized Adjusted Diagnosed Incidence of AML, Ages ≥18 Years, 2016

Figure 7: 7MM, Sources Used and Not Used, Diagnosed Incident Cases of AML

Figure 8: 7MM Sources Used, Relative Survival of AML

Figure 9: 7MM, Sources Used, Diagnosed Incident Cases of APL

Figure 10: 7MM, Sources Used, Diagnosed Incident Cases of Secondary AML

Figure 11: 7MM, Diagnosed Incident Cases of APL, Both Sexes, Ages ≥18 Years, 2016

Figure 12: 7MM, Diagnosed Incident Cases of Secondary AML, Both Sexes, Ages ≥18 Years, 2016

Figure 13: 7MM, Diagnosed Incident Cases of AML by Risk Group, Both Sexes, Ages ≥18 Years, 2016

Figure 14: 7MM, Five-Year Diagnosed Prevalent Cases of AML by Age, Both Sexes, 2016

Figure 15: Disease Management Flowchart for AML in Patients Younger Than 60 Years

Figure 16: Disease Management Flowchart for AML in Elderly Patients

Figure 17: Dacogen’s Development in AML

Figure 18: Vidaza’s Development in AML

Figure 19: Mylotarg’s Development in AML

Figure 20: Rydapt’s (Midostaurin’s) Development in AML

Figure 21: Overview of The Clinical Development Pipeline in AML

Figure 22: CC-486’s Development in AML

Figure 23: Guadecitabine’s (SGI-110) Development in AML

Figure 24: Gilteritinib (ASP2215)’s Development in AML

Figure 25: Quizartinib’s Development in AML

Figure 26: Crenolanib’s Development in AML

Figure 27: Vadastuximab Talirine’s Development in AML

Figure 28: Enasidenib’s Development in AML

Figure 29: Venclexta (Venetoclax)’s Development in AML

Figure 30: Idasanutlin’s Development in AML

Figure 31: Pracinostat’s Development in AML

Figure 32: Iomab-B’s Development in AML

Figure 33: Volasertib’s Development in AML

Figure 34: Ganetespib’s Development in AML

Figure 35: Vyxeos’ Development in AML

Figure 36: Qinprezo’s (vosaroxin) Development in AML

Figure 37: Sapacitabine’s Development in AML

Figure 38: NiCord’s Development in AML

Figure 39: Competitive Assessment of Marketed and Pipeline Agents For Elderly AML Patients Who Are Not Eligible For Intensive Therapy (60 Years And Older), 2016–2026

Figure 40: Competitive Assessment of Marketed and Pipeline Agents For Young And Elderly AML Patients Who Are Eligible For Intensive Therapy (18 Years And Older), 2016–2026

Figure 41: Competitive Assessment of Marketed and Pipeline Agents For FLT3+ AML Patients (18 Years And Older), 2016–2026

Figure 42: Top-Line Sales for AML by Country/Region, 2016 and 2026

Figure 43: Global Sales for AML by Drug Class, 2016 and 2026

Figure 44: Global Sales for AML by Drug Class in the US, 2016 and 2026

Figure 45: Global Sales for AML by Drug Class in the 5EU, 2016 and 2026

Figure 46: Global Sales for AML by Drug Class in Japan, 2016 and 2026

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports